New hope for brain lymphoma: drug cocktail shows promise in early trial
NCT ID NCT07191431
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 23 times
Summary
This study is testing a combination of three drugs (orelabrutinib, selinexor, and either methotrexate or alternatives) in 25 people with relapsed or refractory central nervous system lymphoma (CNSL), a type of brain cancer that has not responded to prior treatment. The goal is to see if this new mix can shrink tumors and control the disease longer. Participants will receive the drugs in 3-week cycles, and those who respond may continue with maintenance therapy. This is an early-stage trial focused on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA CNS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.